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1 	 | 	 INTRODUCTION
Immune-	mediated	 thrombocytopenia	 (ITP)	 is	an	autoim-
mune	condition	characterized	by	 low	platelet	counts	and	
wide	 range	of	 clinical	manifestations	 from	asymptomatic	
presentation	 to	 major	 bleeding	 manifestations.	 Vaccine-	
mediated	secondary	ITP	is	rare	and	is	associated	with	in-
fluenza,	measles	mumps	rubella	 (MMR),	and	hepatitis	A	






with	 steroids	 and	 IVIG	 and	 was	 eventually	 treated	 with	
combination	 of	 romiplostim	 and	 mycophenolate	 mofetil	
(MMF)	with	which	her	counts	improved	dramatically.
2 	 | 	 CASE DISCUSSION













and	 severe	 thrombocytopenia	 with	 a	 platelet	 count	 of	 1	
×	 109/L.	 Prothrombin	 time	 (PT/INR),	 activated	 partial	
thromboplastin	time	(aPTT),	fibrinogen,	lactate	dehydro-
genase	(LDH),	absolute	reticulocyte	count,	and	haptoglo-
bin	 levels	 were	 within	 normal	 limits.	 Peripheral	 blood	
smear	 showed	 profound	 thrombocytopenia	 with	 no	 evi-
dence	of	schistocytes.	RT-	PCR	testing	for	SARS-	CoV-	2	in-
fection	was	negative.	Autoimmune	and	infectious	workup	
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worsening	 during	 the	 second	 and	 third	 day	 of	 hospital-
ization	 and	 developed	 multiple	 bleeding	 sites	 including	
gross	 hematuria,	 hematochezia,	 and	 subconjunctival	



















follow-	up,	 platelet	 count	 recovered	 to	 268	 ×	 109/L	 and	
MMF	was	tapered	down	to	500	mg	twice	daily	and	romi-
plostim	 to	 2  mcg/kg.	 By	 fifth-	week,	 her	 platelet	 counts	















ranial	 hemorrhage,	 which	 usually	 occur	 when	 platelet	
count	is	below	10	×	109/L.2
Vaccination	 as	 an	 etiology	 for	 secondary	 ITP	 was	
previously	 reported	 with	 influenza,	 hepatitis	 A	 and	 B,	
measles,	MMR,	and	diphtheria	tetanus	acellular	pertus-
sis	 (DTaP)	 vaccines.	 It	 is	 hypothesized	 that	 pathogen-
esis	 of	 ITP	 is	 mainly	 secondary	 to	 molecular	 mimicry,	
a	 phenomenon	 in	 which	 host	 antigens	 are	 recognized	
as	 antigens	 of	 immunization,	 provoking	 the	 develop-
ment	of	autoantibodies.	These	antibody-	coated	platelets	
may	 undergo	 reticuloendothelial	 phagocytosis	 result-






bocytopenia	 after	 receiving	 COVID	 vaccination	 with	 ei-
ther	mRNA-	1273	or	Pfizer-	BioNTech	BNT16B2b2	mRNA	
SARS-	CoV-	2	 vaccine.	 Sixteen	 of	 these	 patients	 did	 not	
report	 history	 of	 thrombocytopenia	 prior	 to	 their	 vacci-
nation.4	Onset	of	symptoms	from	the	date	of	vaccination	
ranged	 from	 1	 to	 23	 days.4	 In	 the	 other	 three	 individu-
ally	published	case	reports,	ITP	developed	12	h	to	5	days	
post	 Pfizer-	BioNTech	 BNT16B2b2	 mRNA	 SARS-	CoV-	2	
vaccine	 in	 patients	 who	 previously	 had	 a	 normal	 plate-
let	 count.5–	7	 Similarly,	 our	 patient	 had	 normal	 platelet	
counts	 prior	 to	 this	 presentation.	 ITP	 developed	 on	 day	
26	after	the	second	vaccine	was	given,	which	differs	from	
previously	 reported	 cases	 and,	 so	 far,	 is	 the	 most	 “de-
layed”	onset	reported	in	the	literature.	It	is	not	clear	how	





cine	 immunity.8	 Corticosteroids,	 IVIG	 with	 or	 without	
platelet	 transfusions,	 have	 been	 used	 successfully	 with	
responses	noted	within	4–	6	days.5–	7	 In	the	study	by	Lee	
et	al,	outcomes	were	reported	in	16	patients,	of	which	13	
responded	 to	 the	 initial	 treatment	 with	 IVIG,	 steroids,	
or	 platelet	 transfusion.	 One	 patient	 received	 rituximab,	
romiplostim,	 vincristine	 along	 with	 steroids	 and	 IVIG.	
Another	patient	developed	severe	thrombocytopenia	and	
intracranial	 hemorrhage	 despite	 receiving	 corticoste-
roids,	IVIG,	and	Rituximab.4
In	 our	 case,	 thrombocytopenia	 was	 refractory	 to	 ini-
tial	treatment	with	dexamethasone	and	IVIG.	Due	to	her	
presentation	with	massive	and	multi-	site	bleeding,	 there	
was	 concern	 for	 imminent	 intracranial	 hemorrhage	 in	
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this	 young	 and	 otherwise	 healthy	 female,	 and	 a	 rapid	
response	 to	 treatment	of	her	 refractory	 ITP	seemed	crit-
ical.	 We	 were	 hesitant	 to	 use	 commonly	 recommended	
options	for	refractory	ITP,	such	as	rituximab,	single-	agent	
thrombopoietin-	stimulating	 agent	 (TSA),	 and	 spleen	 ty-
rosine	kinase	inhibitor	fostamatinib	due	to	acuity	of	this	
case.9	 With	 rituximab,	 median	 time	 to	 response	 is	 5.5	
weeks,10	 and	 TSAs	 and	 fostamatinib	 are	 approved	 for	
patients	 with	 chronic	 ITP	 who	 have	 failed	 conventional	
medical	therapy	or	splenectomy.11–	13	Although	promising,	
there	are	 limited	data	 to	support	 the	use	of	 single-	agent	
TSAs	 in	 newly	 diagnosed	 ITP.14	 In	 a	 pooled	 analysis	 of	
phase	III	clinical	 trials	studying	fostamatinib	 in	patients	
with	chronic	ITP,	only	18%	of	patients	achieved	a	stable	











As	 SARS-	CoV-	2	 pandemic	 persists,	 concerns	 for	
vaccine-	related	side	effects	remain,	both	among	caregivers	
and	the	general	population.	As	of	June	26,	2021,	around	
46.4%	 of	 the	 United	 States	 population	 has	 received	 full	
vaccination	against	SARS-	CoV-	2	and	the	risks	of	serious	
adverse	events	remain	extremely	low.	Similar	to	primary	
ITP,	 vaccine-	related	 ITP	 can	 have	 a	 broad	 spectrum	 of	
presentation	ranging	from	mild	bleeding	and	petechiae	to	
fatal	bleeding	manifestations.	When	patients	present	with	
ITP,	 a	 thorough	 vaccination	 history	 is	 needed.	 ITP	 after	
SARS-	CoV-	2	vaccination	is	rare,	and	the	potential	associ-
ation	is	often	overlooked	and	missed.	While	neither	of	the	
clinical	 trials	 studying	 mRNA-	1273	 or	 Pfizer-	BioNTech	
BNT16B2b2	 mRNA	 SARS-	CoV-	2	 vaccine	 had	 docu-
mented	cases	of	 thrombocytopenia,18	 it	 is	worthwhile	 to	
note	 that	 possibility	 of	 reported	 thrombocytopenia	 post-	
vaccination	could	be	merely	a	coincidence	rather	than	a	
causative	 factor.	 Nevertheless,	 we	 are	 probably	 just	 now	
only	at	the	beginning	of	our	understanding	of	the	plethora	
and	complexity	of	side	effects	and	immunological	impact	
of	 the	 SARS-	CoV-	2-	directed	 vaccination	 and	 the	 virus	
itself.	 Continued	 vigilance	 and	 reporting	 of	 the	 possible	
side	effects	of	vaccinations	are	needed,	and	we	believe	this	
should	 not	 preclude	 individuals	 from	 getting	 vaccinated	
given	rarity	of	these	events	and	the	proven	effectiveness	of	
vaccine	in	mitigating	this	horrendous	pandemic.
Further	 studies	 on	 the	 aggressive	 management	 with	
combination	 regimens	 including	 immunosuppressants	
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